Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 6/20 | 0.43 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 6/20 | 0.39 |
| ▸ | SMO | Q99835 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12485986 | 1.00 | BTK (0.43) | BTKS100A4HRH4JAK3MAP4K4 | |
| SCHEMBL12484425 | 0.94 | HRH4 (0.46) | BTKHRH4SMOPKM | |
| SCHEMBL12484429 | 0.94 | HRH4 (0.46) | BTKHRH4SMOPKM | |
| SCHEMBL12485380 | 0.90 | HRH4 (0.41) | BTKS100A4HRH4JAK3LMNA | |
| SCHEMBL12486449 | 0.90 | PDCD1LG2 (0.43) | BTKS100A4HRH4JAK3LMNA | |
| SCHEMBL12486446 | 0.90 | PDCD1LG2 (0.43) | BTKS100A4HRH4JAK3LMNA | |
| SCHEMBL12486601 | 0.84 | JAK3 (0.58) | BTKJAK3MAP4K4 | |
| SCHEMBL12486599 | 0.84 | JAK3 (0.58) | BTKJAK3MAP4K4 | |
| SCHEMBL12485681 | 0.84 | HRH4 (0.49) | BTKS100A4HRH4JAK3 | |
| SCHEMBL12484536 | 0.84 | HRH4 (0.49) | BTKS100A4HRH4JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640490-B2 | Diaminopyrimidine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2020-05-05 | — | — | US | disclosed |
| US-20180072705-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2018-03-15 | — | — | US | disclosed |
| US-9850227-B2 | Diaminopyrimidine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2017-12-26 | — | — | US | disclosed |
| EP-2678331-B1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2016-04-27 | — | — | EP | disclosed |
| EP-2678331-A2 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Yuhan Corporation (KR) | 2014-01-01 | — | — | EP | disclosed |
| US-20130331377-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2013-12-12 | — | — | US | disclosed |
| WO-2012115478-A2 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2012-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331377-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | HRH2, GIPR, SSTR4 | BTK 4572/4885S100A4 1526/4885HRH4 4/4885 |
| US-10640490-B2 | Diaminopyrimidine derivatives and processes for the preparation thereof | HRH2, GIPR, SSTR4 | BTK 4572/4885S100A4 1526/4885HRH4 4/4885 |
| US-20180072705-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | HRH2, GIPR, SSTR4 | BTK 4572/4885S100A4 1526/4885HRH4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.